Vice President Of Research
Current• Head of Discovery Research• Head of Translational Science
Jan 2024 - Present
AeroLeads people directory · profile
Brian Garrison Email & Phone Number
Vice President at Senti Biosciences
at
Senti Biosciences
1 work email found
@sentibio.com
6 phones found area 650, 707, and 617
LinkedIn matched
✓ Verified July 2026
4 data sources
Profile completeness 100%
Current company
Role
Vice President at Senti Biosciences
Location
South San Francisco, California, United States
Who is Brian Garrison? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Brian Garrison is listed as Vice President at Senti Biosciences at Senti Biosciences, based in South San Francisco, California, United States. AeroLeads shows a work email signal at sentibio.com, phone signal with area code 650, 707, 617, and a matched LinkedIn profile for Brian Garrison.
Brian Garrison previously worked as Vice President of Research at Senti Biosciences and Senior Director of Research at Senti Biosciences. Brian Garrison holds Phd, Microbiology And Immunology from Stanford University.
Company email context
Email format at Senti Biosciences
This section adds company-level context without repeating Brian Garrison's masked contact details.
{first}.{last}@sentibio.com
86% confidence
AeroLeads found 1 current-domain work email signal for Brian Garrison. Compare company email patterns before reaching out.
Profile bio
About Brian Garrison
Brian Garrison is Vice President of Research at Senti Biosciences in South San Francisco, CA, where he is Head of both Discovery Research (encompassing 3 teams - Bioinformatics, Gene Circuit Research, Cell Therapy Research) and Translational Research. In his role as Head of Discovery Research, Brian leads discovery and technology development within Senti's cell therapy pipeline, including both liquid and solid tumors. He leads 3 teams whose goal is to use collaborative approaches across cell biology, immunology, synthetic biology, biological programming, and bioinformatics to develop truly innovative “smarter” living medicines with the ability to target diseases in a more focused, controlled, and effective manner. In his role as Head of Translational Research, Brian leads a team who plays key roles in performing IND-enabling studies as well as correlative studies within Senti's clinical trial(s). Brian's commitment to innovation is evident by the multiple cell therapy programs he has overseen, including logic gated and multi-armed CAR-NK/T cell therapy programs. Brian truly believes that innovation is the key to cell therapy success, and that such innovation will require a team effort.
Listed skills include Cell Biology, Molecular Biology, Stem Cells, Cell Culture, and 35 others.
Current workplace
Brian Garrison's current company
Company context helps verify the profile and gives searchers a useful next step.
12 roles · 33 years
Brian Garrison work experience
A career timeline built from the work history available for this profile.
Senior Director Of Research
◦ Head of Discovery Research, encompassing 3 teams (Bioinformatics, Gene Circuit Research, Cell Therapy Research)◦ Lead discovery and technology development within Senti Bio's cell therapy pipeline◦ Oversee strategic early pipeline planning, with direct oversight of multiple CAR cell therapy programs from target identification through to DC Selection and IND-enabling studies◦ Lead cross-functional collaborations to develop Senti Bio’s allogeneic CAR-NK cell platform and pipeline programs◦ Lead external collaborations to further Senti's technology development◦ Forecast and maintain the Discovery Research departmental budget, and collaboratively help manage the broader R&D budget◦ Inform and confer with Senti leadership on status of pipeline programs, challenges, and potential solutions◦ Successfully completed SBIR contract, receiving highest marks◦ Engage, promote, and educate the scientific community about Senti Bio's innovative technologies, often including multiple conference presentation per year◦ Dedicated to providing a positive and supportive work environment that follows Senti Bio's core values: Be Bold! Better Together! Build to Last!
Aug 2022 - Mar 2024
Director Of Research
◦ Head of logic gated CAR-NK cell program for AML◦ Successfully led Senti's first CAR-NK cell program to DC Selection◦ PI on SBIR contract from the NCI for clinical translation of CAR NK cell program◦ Align and support other research teams to ensure fulfillment of R&D and corporate goals
Mar 2021 - Aug 2022
Associate Director Of Research
◦ Head of logic gated CAR-NK cell program for AML◦ Enhanced collaborative team efforts through improved communication and deconstructing of informational silos◦ Successfully led Senti's first CAR-NK cell program through lead selection, which required significant novel technology development for both the activating and inhibitory CARs
Mar 2019 - Mar 2021
Group Leader: Car-T Cell Immunotherapy
◦ Led Senti's first CAR T cell therapy team, for the treatment of AML◦ Successfully led efforts to identify the ideal tumor target antigen pair for a bivalent activating CAR approach for logic gated T/NK cell AML programs◦ Successfully led efforts to identify the ideal inhibitory CAR target for protection of healthy cells from on-target off-tumor toxicity within logic gated CAR T/NK cell AML programs
Jan 2019 - Mar 2019
Group Leader: Cell Technologies
◦ Led a team responsible for identifying and optimizing new cell therapy technologies for Senti Bio
Feb 2018 - Jan 2019
Scientist
◦ Developed Senti Bio's first cell platform for the design, testing, and development of new gene circuit technologies (PMID: 34210826; co-author)
Nov 2016 - Feb 2018
Research Fellow
• Generated and comparatively analyzed transcriptomics data to identify hematopoietic stem cell (HSC)-specific transcription factors, which were then characterized using a variety of in vitro and in vivo functional assays (PMID: 24319662; co-first author)• Identified the transcription factor Zfp521 as a regulator of HSC pool size and MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)• Identified Hlf as a key HSC regulator by demonstrating it could imbue progenitors with stem cell-like attributes• In collaboration with Dr. Timothy Springer laboratory, generated bone marrow-derived microglia for successful therapeutic treatment of a neurological disease caused by defective TGFβ signaling (PMID: 29909984; co-first author)• Utilized HSC transcription factor expertise in collaboration to reprogram hematopoietic cells to a stem cell fate (PMID: 24766805; co-author)• Utilized my HSC and microglia experience in collaboration to achieve engraftment of microglia-like cells in the brain (PMID: 29226242; co-author)• Collaborated with laboratory colleagues on several HSC aging projects (PMID: 25274507, PMID: 23415915; co-author), as well as the first demonstration of CRISPR/Cas9-based ablation of clinically relevant genes in human hematopoietic cells (PMID: 25517468; co-author)(Laboratory of Dr. Derrick J. Rossi)
Jun 2009 - Jan 2017
Research Fellow
• Generated and comparatively analyzed transcriptomics data to identify hematopoietic stem cell (HSC)-specific transcription factors, which were then characterized using a variety of in vitro and in vivo functional assays (PMID: 24319662; co-first author)• Identified the transcription factor Zfp521 as a regulator of HSC pool size and MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)• Identified Hlf as a key HSC regulator by demonstrating it could imbue progenitors with stem cell-like attributes• In collaboration with Dr. Timothy Springer laboratory, generated bone marrow-derived microglia for successful therapeutic treatment of a neurological disease caused by defective TGFβ signaling (PMID: 29909984; co-first author)• Utilized HSC transcription factor expertise in collaboration to reprogram hematopoietic cells to a stem cell fate (PMID: 24766805; co-author)• Utilized my HSC and microglia experience in collaboration to achieve engraftment of microglia-like cells in the brain (PMID: 29226242; co-author)• Collaborated with laboratory colleagues on several HSC aging projects (PMID: 25274507, PMID: 23415915; co-author), as well as the first demonstration of CRISPR/Cas9-based ablation of clinically relevant genes in human hematopoietic cells (PMID: 25517468; co-author)(Laboratory of Dr. Derrick J. Rossi)
Jun 2009 - Jan 2017
Research Fellow
• Utilized a microarray-based approach to identify HSC-specific regulators for possible therapeutic manipulation• Genes of interest were ectopically expressed or knocked-down within in vitro and in vivo functional assays for stem and progenitor cell activity• Studied the role of p57 in biological pathways unique to HSCs, including quiescence and self-renewal• Collaborated with laboratory colleagues on several HSC microenvironment projects (PMID: 18682243; co-author)• Collaborator for study of MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)(Laboratory of Dr. David T. Scadden)
Mar 2006 - Jun 2009
Graduate Student Researcher
• Optimized transposon-mediated gene addition strategies for human gene therapy• Uncovered the extent of post-integrative silencing potential in transposon-mediated gene therapy approaches (PMID: 17938204; first author) while concurrently studying transposon integration site preferences (PMID: 15743807; co-author)(Laboratory of Dr. Mark A. Kay)
1998 - 2005
~7 yrs
Undergraduate Researcher
• Used forward genetic screens to identify and characterize regulators of autophagy (PMID: 10712513; co-author)• Studied the assembly of the yeast vacuolar proton-translocating ATPase (PMID: 9195975; co-author)(Laboratory of Dr. Daniel J. Klionsky)
1994 - 1998
~4 yrs
2 education records
Brian Garrison education
Phd, Microbiology And Immunology
Stanford University
Bs, Microbiology
University Of California, Davis
FAQ
Frequently asked questions about Brian Garrison
Quick answers generated from the profile data available on this page.
What company does Brian Garrison work for?
Brian Garrison works for Senti Biosciences.
What is Brian Garrison's role at Senti Biosciences?
Brian Garrison is listed as Vice President at Senti Biosciences at Senti Biosciences.
What is Brian Garrison's email address?
AeroLeads has found 1 work email signal at @sentibio.com for Brian Garrison at Senti Biosciences.
What is Brian Garrison's phone number?
AeroLeads has found 6 phone signal(s) with area code 650, 707, 617 for Brian Garrison at Senti Biosciences.
Where is Brian Garrison based?
Brian Garrison is based in South San Francisco, California, United States while working with Senti Biosciences.
What companies has Brian Garrison worked for?
Brian Garrison has worked for Senti Biosciences, Harvard University, Boston Children'S Hospital, Massachusetts General Hospital, and Stanford University.
How can I contact Brian Garrison?
You can use AeroLeads to view verified contact signals for Brian Garrison at Senti Biosciences, including work email, phone, and LinkedIn data when available.
What schools did Brian Garrison attend?
Brian Garrison holds Phd, Microbiology And Immunology from Stanford University.
What skills is Brian Garrison known for?
Brian Garrison is listed with skills including Cell Biology, Molecular Biology, Stem Cells, Cell Culture, Cell, Clinical Research, Biochemistry, and Genetics.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial